| 3.5 -0.12 (-3.31%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.51 |
1-year : | 4.87 |
| Resists | First : | 3.86 |
Second : | 4.17 |
| Pivot price | 3.58 |
|||
| Supports | First : | 3.38 | Second : | 2.81 |
| MAs | MA(5) : | 3.54  |
MA(20) : | 3.62 |
| MA(100) : | 4 |
MA(250) : | 3.86 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 32.2 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 5.78 | Low : | 1.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IRWD ] has closed above bottom band by 26.5%. Bollinger Bands are 56.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.64 - 3.66 | 3.66 - 3.67 |
| Low: | 3.41 - 3.43 | 3.43 - 3.45 |
| Close: | 3.47 - 3.5 | 3.5 - 3.52 |
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Fri, 30 Oct 2026
Ironwood Pharmaceuticals, Inc. (IRWD) Seasonal returns chart - Yahoo Finance UK
Thu, 29 Oct 2026
Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 28 Oct 2026
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call - Yahoo Finance
Wed, 28 Oct 2026
Bank of America reports an Ironwood Pharmaceuticals (IRWD) stake with no sole voting power. - Stock Titan
Wed, 28 Oct 2026
IRWD Q3'26 Earnings: EPS estimate is 0.32 USD - TradingView
Fri, 23 Oct 2026
Ironwood Pharmaceuticals, Inc. Estimates – NASDAQ:IRWD - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 165 (M) |
| Shares Float | 137 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 98.9 (%) |
| Shares Short | 15,570 (K) |
| Shares Short P.Month | 17,650 (K) |
| EPS | 0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.99 |
| Profit Margin | 33.3 % |
| Operating Margin | 70.1 % |
| Return on Assets (ttm) | 47 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 32.5 % |
| Gross Profit (p.s.) | 1.81 |
| Sales Per Share | 2.35 |
| EBITDA (p.s.) | 1.44 |
| Qtrly Earnings Growth | 125.6 % |
| Operating Cash Flow | 186 (M) |
| Levered Free Cash Flow | 122 (M) |
| PE Ratio | 4.54 |
| PEG Ratio | 0 |
| Price to Book value | -3.58 |
| Price to Sales | 1.48 |
| Price to Cash Flow | 3.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|